-
-
-
-
-
-
-
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
-
-
-
-
-
-
-
Journey Medical expands Emrosi payer coverage to 65% of commercial lives
-
-
-
-
-
-
-
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Journey Medical Corporation Announces Publication in the Journal of the American Medical Association - Dermatology of the Phase 3 Clinical Trial Results of Emrosi™ (DFD-29) to Treat Rosacea
-
-
-
-
-
-
-
Journey Medical Corporation Announces DFD-29 Data Presented at 44th Fall Clinical Dermatology Conference
-
-
-
-
-
-
-
Journey Medical Corporation Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
-
-
-
-
-
-
-
Journey Medical Corp (DERM) Announces Presentation of Data from Phase 1 Trial of DFD-29
-
1,186,423 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

